Aarey Drugs & Pharmaceuticals Ltd disclosed that its promoter group converted convertible warrants into 2,520,000 equity shares on September 30, 2026. The allotment, valued at approximately ₹1.21 crore, marks a shift in the holding structure of seven key promoter entities.

The transaction was executed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, pursuant to Regulation 7(2)(b). Additionally, disclosures were made under Regulation 29(2) read with Regulation 29(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosures were submitted to the National Stock Exchange of India and BSE Limited on October 3, 2026. The conversions involved multiple members of the Ghatalia family, including Bina Rajesh Ghatalia, Mihir Rajesh Ghatalia, and Nimit Rajesh Ghatalia.

Promoter holding changes

The conversion resulted in a net increase in the number of equity shares held by the promoter group, while their convertible warrant holdings decreased correspondingly. The table below details the specific changes for each promoter entity:

Consolidated promoter group stake

Following the allotment, the total shareholding of the promoter and promoter group entities increased to 13,212,443 shares, representing 41.45% of the total voting capital. This is an increase from the pre-conversion holding of 10,692,442 shares (37.71%). The equity share capital of the company rose from 28,354,303 to 30,724,303 shares post-allotment, with a diluted capital of 33,354,303 shares.

What the numbers show

The aggregate value of the allotted shares stands at ₹1,20,58,250. A notable divergence appears in the percentage shareholding figures for two individuals: Mihir Rajesh Ghatalia’s stake dipped from 10.00% to 9.98%, while Mira Mihir Ghatalia’s holding rose from 2.43% to 2.95%. This indicates that while the absolute number of shares increased for both, the dilution effect from the total outstanding share capital impacted the percentage metrics differently for each entity. Additionally, Ekta Nimit Ghatalia and the HUF entity moved from holding only warrants to holding equity shares, diversifying the nature of their assets within the company. The consolidated promoter stake crossing the 40% threshold reinforces control stability despite the dilution of individual percentage holdings due to the new issuance.

Aarey Drugs & Pharmaceuticals has notified stock exchanges that it sent letters to shareholders without registered email addresses, providing a web link to access the Integrated Annual Report for FY26. The disclosure was made on September 11, 2026.

The company informed the Bombay Stock Exchange and the National Stock Exchange regarding the issuance of these letters pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action ensures that members who have not registered their email addresses with the company or depository participants can still access the financial documents.

Annual Report Access Details

The letters were sent to shareholders as on the cut-off date of September 4, 2026. The Integrated Annual Report for the financial year ended March 31, 2026, is available on the company's website. Shareholders can access the document via the investors section of the official site.

Nimit Ghatalia, Director of the company, issued the notification to the exchanges. Mr. Kailash Chand Jethlia, Company Secretary and Compliance Officer, signed the letter to shareholders. The company encourages investors to update their email addresses through depository participants or the registrar to facilitate future communications and support green initiatives.

AGM and Book Closure Reminder

The company previously scheduled its 36th Annual General Meeting for Wednesday, September 30, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means. The book closure period runs from September 24, 2026, to September 30, 2026. Shareholders holding shares as of the record date will be eligible to attend the meeting and vote on resolutions.

The primary business includes adopting the audited financial statements for the year ended March 31, 2026. Shareholders will also vote on the reappointment of Mrs. Bina Ghatalia as a director and approve related party transactions. E-voting is open between September 27, 2026, at 9:00 am and September 29, 2026, at 5:00 pm.